癌胚抗原和细胞角蛋白19片段作为晚期非小细胞肺癌预后因素的研究
Carcinoembryonic antigen and CYFRA 21-1 responses as prognostic factors in advanced non-small cell lung cancer.
作者信息
Yoshimura Akihiro, Uchino Junji, Hasegawa Koichi, Tsuji Taisuke, Shiotsu Shinsuke, Yuba Tatsuya, Takumi Chieko, Yamada Tadaaki, Takayama Koichi, Hiraoka Noriya
机构信息
Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.
出版信息
Transl Lung Cancer Res. 2019 Jun;8(3):227-234. doi: 10.21037/tlcr.2019.06.08.
BACKGROUND
It is unclear whether changes in serum tumor marker expression post-treatment are of prognostic value. We investigated the associations between changes in serum carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (CYFRA 21-1) after first-line treatment and overall survival (OS) in non-small cell lung cancer (NSCLC).
METHODS
Advanced NSCLC patients (April 2010 to December 2015) with elevated serum CEA or CYFRA 21-1 were included. The associations between tumor marker changes after treatment initiation and OS were analyzed.
RESULTS
Ninety-six and 55 patients were CEA- and CYFRA 21-1-positive, respectively. The serum CEA response at 4 months and CYFRA 21-1 responses at 1 and 4 months were significantly associated with OS in the univariate analyses (P=0.025, P=0.016 and P<0.001, respectively). Moreover, in the multivariate analyses, serum CYFRA 21-1 response at 4 months was significantly associated with improved OS (P=0.038).
CONCLUSIONS
In NSCLC patients, serum CEA and CYFRA 21-1 responses after treatment initiation may predict longer OS.
背景
治疗后血清肿瘤标志物表达的变化是否具有预后价值尚不清楚。我们研究了一线治疗后血清癌胚抗原（CEA）和细胞角蛋白19片段（CYFRA 21-1）的变化与非小细胞肺癌（NSCLC）总生存期（OS）之间的关联。
方法
纳入2010年4月至2015年12月期间血清CEA或CYFRA 21-1升高的晚期NSCLC患者。分析治疗开始后肿瘤标志物变化与OS之间的关联。
结果
分别有96例和55例患者CEA和CYFRA 21-1呈阳性。单因素分析中，4个月时的血清CEA反应以及1个月和4个月时的CYFRA 21-1反应与OS显著相关（P分别为0.025、0.016和P<0.001）。此外，多因素分析中，4个月时的血清CYFRA 21-1反应与OS改善显著相关（P=0.038）。
结论
在NSCLC患者中，治疗开始后血清CEA和CYFRA 21-1反应可能预示更长的OS。
Zotero 插件